Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease

Nature Clinical Practice Nephrology

Volumn 4, Issue 9, 2008, Pages 488-489

  Gallieni, Maurizio ^a   Cozzolino, Mario ^a   Ronga, Chiara ^a   Brancaccio, Diego ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE SULFATE; TINZAPARIN;

BLEEDING; CHRONIC KIDNEY DISEASE; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MONITORING; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEMODIALYSIS PATIENT; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; OSTEOPOROSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; SHORT SURVEY; THROMBOSIS;

HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; KIDNEY FAILURE, CHRONIC; PULMONARY EMBOLISM; RENAL DIALYSIS; VENOUS THROMBOSIS;

EID: 50249102693     PISSN: 17458323     EISSN: 17458331     Source Type: Journal    
DOI: 10.1038/ncpneph0879     Document Type: Short Survey

References (11)

1. Levine M et al. (1996) A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 334: 677-681
2. Centers for Disease Control and Prevention (CDC) (2008) Acute allergic-type reactions among patients undergoing hemodialysis-multiple states, 2007-2008. MMWR Morb Mortal Wkly Rep 57: 124-125
3. Lim W et al. (2004) Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 15: 3192-3206
4. Farooq V et al. (2004) Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 43: 531-537
5. Gerlach AT et al. (2000) Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 20: 771-775
6. Guillet B et al. (2003) Pharmacokinetics of the low molecular weight heparin enoxaparin during 48 h after bolus administration as an anticoagulant in haemodialysis. Nephrol Dial Transplant 18: 2348-2353
7. Lim W et al. (2006) Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 144: 673-684
8. Crowther MA et al. (2002) Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol 116: 178-186
9. Hulot JS et al. (2005) Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 77: 542-552
10. Hetzel GR and Sucker C (2005) The heparins: all a nephrologist should know. Nephrol Dial Transplant 20: 2036-2042
11. Hirsh J and Raschke R (2004) Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 126 (Suppl): 188S-203S